Bio-Rad Laboratories, Inc. (BIO.B) stock
BIO.BNYSELaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BIO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 8/3055% above fair value
$379.50+0.00 (0.00%)
Close on Oct 29, 2026Market cap $10.18BP/E 46.2Yield –
Bio-Rad Laboratories operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Bio-Rad Laboratories's operating cash flow for the twelve months ending Jun 30, 2026 was $492.60M, down 7.8% year over year. For fiscal 2025 it was $532.20M, up 16.9% from the year before. Over ten years it grew 11.1% a year on average. The highest annual figure on record is $669.46M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $532.20M | +16.9% |
| FY2024 | Dec 31, 2024 | $455.20M | +21.4% |
| FY2023 | Dec 31, 2023 | $374.90M | +92.8% |
| FY2022 | Dec 31, 2022 | $194.40M | -71.0% |
| FY2021 | Dec 31, 2021 | $669.46M | +14.4% |
| FY2020 | Dec 31, 2020 | $584.97M | +27.8% |
| FY2019 | Dec 31, 2019 | $457.90M | +60.4% |
| FY2018 | Dec 31, 2018 | $285.49M | +174.2% |
| FY2017 | Dec 31, 2017 | $104.14M | -51.8% |
| FY2016 | Dec 31, 2016 | $216.07M | +16.0% |
| FY2015 | Dec 31, 2015 | $186.21M | -31.9% |
| FY2014 | Dec 31, 2014 | $273.31M | +61.6% |
| FY2013 | Dec 31, 2013 | $169.14M | -36.5% |
| FY2012 | Dec 31, 2012 | $266.48M | +1.4% |
| FY2011 | Dec 31, 2011 | $262.74M | +16.3% |
| FY2010 | Dec 31, 2010 | $225.91M | -30.5% |
| FY2009 | Dec 31, 2009 | $325.07M | +69.9% |
| FY2008 | Dec 31, 2008 | $191.37M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $98.70M | -15.3% |
| Q1 FY2026 | Mar 31, 2026 | $108.10M | -16.8% |
| Q4 FY2025 | Dec 31, 2025 | $164.90M | +32.8% |
| Q3 FY2025 | Sep 30, 2025 | $120.90M | -26.1% |
| Q2 FY2025 | Jun 30, 2025 | $116.50M | +19.4% |
| Q1 FY2025 | Mar 31, 2025 | $129.90M | +86.1% |
| Q4 FY2024 | Dec 31, 2024 | $124.20M | +53.3% |
| Q3 FY2024 | Sep 30, 2024 | $163.60M | +67.4% |
| Q2 FY2024 | Jun 30, 2024 | $97.60M | -0.5% |
| Q1 FY2024 | Mar 31, 2024 | $69.80M | -28.9% |
| Q4 FY2023 | Dec 31, 2023 | $81.00M | +1.8% |
| Q3 FY2023 | Sep 30, 2023 | $97.71M | +786.1% |
| Q2 FY2023 | Jun 30, 2023 | $98.07M | +84.1% |
| Q1 FY2023 | Mar 31, 2023 | $98.12M | +94.3% |
| Q4 FY2022 | Dec 31, 2022 | $79.61M | -53.4% |
| Q3 FY2022 | Sep 30, 2022 | $11.03M | -95.2% |
| Q2 FY2022 | Jun 30, 2022 | $53.27M | -65.5% |
| Q1 FY2022 | Mar 31, 2022 | $50.49M | -55.6% |
| Q4 FY2021 | Dec 31, 2021 | $170.87M | -42.0% |
| Q3 FY2021 | Sep 30, 2021 | $230.36M | +69.8% |
| Q2 FY2021 | Jun 30, 2021 | $154.62M | +67.8% |
| Q1 FY2021 | Mar 31, 2021 | $113.61M | +80.9% |
| Q4 FY2020 | Dec 31, 2020 | $294.38M | +84.2% |
| Q3 FY2020 | Sep 30, 2020 | $135.66M | +36.0% |
| Q2 FY2020 | Jun 30, 2020 | $92.12M | -40.7% |
| Q1 FY2020 | Mar 31, 2020 | $62.81M | +46.3% |
| Q4 FY2019 | Dec 31, 2019 | $159.80M | +52.2% |
| Q3 FY2019 | Sep 30, 2019 | $99.75M | +60.2% |
| Q2 FY2019 | Jun 30, 2019 | $155.40M | +99.6% |
| Q1 FY2019 | Mar 31, 2019 | $42.94M | +6.4% |
| Q4 FY2018 | Dec 31, 2018 | $105.01M | +51.4% |
| Q3 FY2018 | Sep 30, 2018 | $62.28M | +118.7% |
| Q2 FY2018 | Jun 30, 2018 | $77.86M | +24.6% |
| Q1 FY2018 | Mar 31, 2018 | $40.35M | – |
| Q4 FY2017 | Dec 31, 2017 | $69.37M | -26.8% |
| Q3 FY2017 | Sep 30, 2017 | $28.48M | -44.8% |
| Q2 FY2017 | Jun 30, 2017 | $62.50M | – |
| Q1 FY2017 | Mar 31, 2017 | -$56.20M | – |
| Q4 FY2016 | Dec 31, 2016 | $94.75M | – |
| Q3 FY2016 | Sep 30, 2016 | $51.61M | – |